Sacituzumab tirumotecan is a special medicine being tested for patients with cervical cancer that has returned or spread. This study compares its effects to the treatment of physician's choice, which means the doctor decides the best treatment for the patient. Cervical cancer is when cells in the cervix grow abnormally, and metastatic means the cancer has spread to other body parts.

The study has two parts: an early safety check to see if sacituzumab tirumotecan is safe and effective, and a bigger Phase 3 trial to compare it with other treatments. The goal is to see if sacituzumab tirumotecan helps patients live longer, especially those with high levels of a protein called TROP2, which is found on some cancer cells.

• The study is for women over 18 with specific types of cervical cancer.
• Patients cannot join if they have certain health conditions or recent treatments.
• Participants will be closely monitored for safety and effectiveness.

Before joining, talk with your doctor to see if this study is right for you and understand the potential benefits and risks.